vs
Side-by-side financial comparison of ACME UNITED CORP (ACU) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $52.3M, roughly 1.1× ACME UNITED CORP). ACME UNITED CORP runs the higher net margin — 1.9% vs -92.6%, a 94.4% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs 13.8%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs -2.9%).
Acme United Corporation is a supplier of cutting, measuring and safety products for the school, home, office, hardware and industrial markets. The company was organized as a partnership in 1867 and incorporated in 1873 under the laws of the State of Connecticut. It is publicly traded on the NYSE American with symbol ACU.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
ACU vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $52.3M | $60.1M |
| Net Profit | $985.0K | $-55.6M |
| Gross Margin | 39.7% | 88.1% |
| Operating Margin | 3.3% | -87.1% |
| Net Margin | 1.9% | -92.6% |
| Revenue YoY | 13.8% | 83.8% |
| Net Profit YoY | -40.4% | — |
| EPS (diluted) | $0.24 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $52.3M | $60.1M | ||
| Q4 25 | $47.5M | $57.3M | ||
| Q3 25 | $49.1M | $51.3M | ||
| Q2 25 | $54.0M | $48.5M | ||
| Q1 25 | $46.0M | $32.7M | ||
| Q4 24 | $45.9M | $41.8M | ||
| Q3 24 | $48.2M | $33.3M | ||
| Q2 24 | $55.4M | $29.1M |
| Q1 26 | $985.0K | $-55.6M | ||
| Q4 25 | $1.9M | $-47.5M | ||
| Q3 25 | $1.9M | $-52.9M | ||
| Q2 25 | $4.8M | $-46.6M | ||
| Q1 25 | $1.7M | $-49.5M | ||
| Q4 24 | $1.7M | $-43.3M | ||
| Q3 24 | $2.2M | $-43.6M | ||
| Q2 24 | $4.5M | $-32.3M |
| Q1 26 | 39.7% | 88.1% | ||
| Q4 25 | 38.2% | 91.6% | ||
| Q3 25 | 39.1% | 89.3% | ||
| Q2 25 | 41.0% | 88.6% | ||
| Q1 25 | 39.0% | 88.8% | ||
| Q4 24 | 38.7% | 90.9% | ||
| Q3 24 | 38.5% | 88.5% | ||
| Q2 24 | 40.8% | 89.9% |
| Q1 26 | 3.3% | -87.1% | ||
| Q4 25 | 6.1% | -82.2% | ||
| Q3 25 | 6.1% | -102.6% | ||
| Q2 25 | 11.8% | -93.4% | ||
| Q1 25 | 5.3% | -143.7% | ||
| Q4 24 | 5.0% | -98.6% | ||
| Q3 24 | 6.1% | -132.0% | ||
| Q2 24 | 11.5% | -139.2% |
| Q1 26 | 1.9% | -92.6% | ||
| Q4 25 | 3.9% | -83.0% | ||
| Q3 25 | 3.9% | -103.1% | ||
| Q2 25 | 8.8% | -96.1% | ||
| Q1 25 | 3.6% | -151.4% | ||
| Q4 24 | 3.7% | -103.6% | ||
| Q3 24 | 4.6% | -131.2% | ||
| Q2 24 | 8.0% | -110.9% |
| Q1 26 | $0.24 | $-0.83 | ||
| Q4 25 | $0.46 | $-0.73 | ||
| Q3 25 | $0.46 | $-0.82 | ||
| Q2 25 | $1.16 | $-0.75 | ||
| Q1 25 | $0.41 | $-0.81 | ||
| Q4 24 | $0.43 | $-0.71 | ||
| Q3 24 | $0.54 | $-0.73 | ||
| Q2 24 | $1.09 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $340.6M |
| Total DebtLower is stronger | $33.0M | — |
| Stockholders' EquityBook value | $116.7M | $122.9M |
| Total Assets | $195.2M | $442.3M |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.2M | $340.6M | ||
| Q4 25 | $3.6M | $388.9M | ||
| Q3 25 | $5.1M | $416.1M | ||
| Q2 25 | $3.6M | $291.0M | ||
| Q1 25 | $3.4M | $314.5M | ||
| Q4 24 | $6.4M | $320.6M | ||
| Q3 24 | $5.7M | $298.4M | ||
| Q2 24 | $3.8M | $319.1M |
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $116.7M | $122.9M | ||
| Q4 25 | $117.6M | $139.1M | ||
| Q3 25 | $115.8M | $148.8M | ||
| Q2 25 | $113.7M | $-11.9M | ||
| Q1 25 | $108.3M | $18.9M | ||
| Q4 24 | $107.0M | $21.7M | ||
| Q3 24 | $106.3M | $11.2M | ||
| Q2 24 | $104.0M | $39.3M |
| Q1 26 | $195.2M | $442.3M | ||
| Q4 25 | $171.0M | $480.2M | ||
| Q3 25 | $173.0M | $506.9M | ||
| Q2 25 | $170.9M | $372.7M | ||
| Q1 25 | $163.0M | $386.7M | ||
| Q4 24 | $162.2M | $392.3M | ||
| Q3 24 | $165.5M | $363.6M | ||
| Q2 24 | $173.5M | $381.8M |
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
